1. Thompson, AJ, Baranzini, SE, Geurts, J, et al. Multiple sclerosis. Lancet (London, England) 2018; 391: 1622–1636.
Google Scholar | Crossref | Medline2. Goldenberg, MM . Multiple sclerosis review. P T 2012; 37: 175–184.
Google Scholar | Medline3. Lublin, FD, Reingold, SC, Cohen, JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278–286.
Google Scholar | Crossref | Medline4. Pardo, G, Jones, DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol 2017; 264: 2351–2374.
Google Scholar | Crossref | Medline5. Chataway, J . Evolving diagnostic criteria for multiple sclerosis. Lancet Neurol 2018; 17: 118.
Google Scholar | Crossref | Medline6. Fischer, S, Proschmann, U, Akgün, K, et al. Lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects. Cells 2021; 10: 3177.
Google Scholar | Crossref | Medline7. Ziemssen, T, Kern, R, Thomas, K. Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach. BMC Neurol 2016; 16: 124.
Google Scholar | Crossref | Medline8. Ziemssen, T, Hillert, J, Butzkueven, H. The importance of collecting structured clinical information on multiple sclerosis. BMC Med 2016; 14: 81.
Google Scholar | Crossref | Medline9. Berger, JR . Neurologists: the last bedside physician-scientists. JAMA Neurol 2013; 70: 965–966.
Google Scholar | Crossref | Medline10. Freedman, MS, Devonshire, V, Duquette, P, et al. Treatment optimization in multiple sclerosis: Canadian MS working group recommendations. Can J Neurol Sci 2020; 47: 437–455.
Google Scholar | Crossref | Medline11. Rotstein, D, Montalban, X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 2019. DOI: 10.1038/s41582-019-0170-8.
Google Scholar | Crossref | Medline12. Voigt, I, Inojosa, H, Dillenseger, A, et al. Digital twins for multiple sclerosis. Front Immunol 2021; 12: 669811.
Google Scholar | Crossref | Medline13. Feys, P, Giovannoni, G, Dijsselbloem, N, et al. The importance of a multi-disciplinary perspective and patient activation programmes in MS management. Mult Scler 2016; 22: 34–46.
Google Scholar | SAGE Journals14. Ziemssen, T, De Stefano, N, Sormani, MP, et al. Optimizing therapy early in multiple sclerosis: an evidence-based view. Mult Scler Relat Dis 2015; 4: 460–469.
Google Scholar | Crossref | Medline15. Thompson, AJ, Banwell, BL, Barkhof, F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162–173.
Google Scholar | Crossref | Medline16. Miller, DH, Chard, DT, Ciccarelli, O. Clinically isolated syndromes. Lancet Neurol 2012; 11: 157–169.
Google Scholar | Crossref | Medline17. Zivadinov, R, Yella, V, Divyer, M, et al. Evidence for cortical atrophy in patients with clinically isolated syndrome. Mult Scler 2006; 12: S175.
Google Scholar18. Tintoré, M . Early MS treatment. Int MS J 2007; 14: 5–10.
Google Scholar | Medline19. Beck, RW, Chandler, DL, Cole, SR, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002; 51: 481–490.
Google Scholar | Crossref | Medline20. Jacobs, LD, Beck, RW, Simon, JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group. N Engl J Med 2000; 343: 898–904.
Google Scholar | Crossref | Medline21. Comi, G, Filippi, M, Barkhof, F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576–1582.
Google Scholar | Crossref | Medline22. Kappos, L, Polman, CH, Freedman, MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242–1249.
Google Scholar | Crossref | Medline23. Comi, G, Martinelli, V, Rodegher, M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503–1511.
Google Scholar | Crossref | Medline24. Wiendl, H, Gold, R, Berger, T, et al. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper) [Position Paper Regarding Disease-modyfing Therapies for Multiple Sclerosis 2021]. Der Nervenarzt 2021; 92: 773–801.
Google Scholar | Crossref | Medline25. Tornatore, C, Phillips, JT, Khan, O, et al. Consensus opinion of US neurologists on practice patterns in RIS, CIS, and RRMS: evolution of treatment practices. Neurol Clin Pract 2016; 6: 329–338.
Google Scholar | Crossref | Medline26. Montalban, X, Gold, R, Thompson, AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018; 24: 96–120.
Google Scholar | SAGE Journals27. Wattjes, MP, Ciccarelli, O, Reich, DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021; 20: 653–670.
Google Scholar | Crossref | Medline28. Ciccone, A, Beretta, S, Brusaferri, F, et al. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev 2008; 1: CD006264.
Google Scholar29. Berkovich, R . Treatment of acute relapses in multiple sclerosis. Neurotherapeutics 2013; 10: 97–105.
Google Scholar | Crossref | Medline30. Giovannoni, G, Butzkueven, H, Dhib-Jalbut, S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord 2016; 9: S5–S48.
Google Scholar | Crossref | Medline31. Hobart, J, Bowen, A, Pepper, G, et al. International consensus on quality standards for brain health-focused care in multiple sclerosis. Mult Scler 2019; 25: 1809–1818.
Google Scholar | SAGE Journals32. Comi, G, Martinelli, V, Rodegher, M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 2012; 19: 1074–1083.
Google Scholar | SAGE Journals33. Kinkel, RP, Dontchev, M, Kollman, C, et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012; 69: 183–190.
Google Scholar | Medline34. Edan, G, Freedman, M, Montalban, X, et al. Long-term Impact of early MS treatment with interferon Beta-1b (IFNB-1b): clinical, MRI, employment, and patient-reported outcomes (PROs) at the 11-year follow-up of BENEFIT (BENEFIT 11)(P7. 012). J Neurol Neurosurg Psychiatry 2014; 85: 1183–1189.
Google Scholar | Crossref | Medline35. Armoiry, X, Kan, A, Melendez-Torres, GJ, et al. Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis. J Neurol 2018; 265: 999–1009.
Google Scholar | Crossref | Medline36. Ziemssen, T, Derfuss, T, de Stefano, N, et al. Optimizing treatment success in multiple sclerosis. J Neurol 2016; 263: 1053–1065.
Google Scholar | Crossref | Medline37. Tedeholm, H, Lycke, J, Skoog, B, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler 2013; 19: 765–774.
Google Scholar | SAGE Journals38. Capra, R, Cordioli, C, Rasia, S, et al. Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS. Mult Scler 2017; 23: 1757–1761.
Google Scholar | SAGE Journals39. University of California San Francisco MS-EPIC Team : Cree, BA, Gourraud, PA, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 2016; 80: 499–510.
Google Scholar | Crossref | Medline40. Brown, JWL, Coles, A, Horakova, D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019; 321: 175–187.
Google Scholar | Crossref | Medline41. Schriefer, D, Haase, R, Ness, NH, et al. Cost of illness in multiple sclerosis by disease characteristics - a review of reviews. Expert Rev Pharm Out 2021. DOI: 10.1080/14737167.2022.1987218.
Google Scholar42. Claflin, SB, Broadley, S, Taylor, BV. The effect of disease modifying therapies on disability progression in multiple sclerosis: a systematic overview of meta-analyses. Front Neurol 2019; 9: 1150–1150.
Google Scholar | Crossref | Medline43. Río, J, Castilló, J, Rovira, A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009; 15: 848–853.
Google Scholar | SAGE Journals44. Rieckmann, P, Traboulsee, A, Devonshire, V, et al. Escalating immunotherapy of multiple sclerosis. Ther Adv Neurol Disord 2008; 1: 181–192.
Google Scholar | SAGE Journals45. Gajofatto, A, Benedetti, MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop. ? World J Clin Cases 2015; 3: 545–555.
Google Scholar | Crossref | Medline46. Harding, K, Williams, O, Willis, M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 2019; 76: 536–541.
Google Scholar | Crossref | Medline47. Furneri, G, Santoni, L, Ricella, C, et al. Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy. BMC Health Services Research 2019; 19: 436.
Google Scholar | Crossref | Medline48. Maruszczak, MJ, Montgomery, SM, Griffiths, MJS, et al. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. J Med Econ 2015; 18: 874–885.
Google Scholar | Crossref | Medline49. Ness, NH, Schriefer, D, Haase, R, et al. Differentiating societal costs of disability worsening in multiple sclerosis. J Neurol 2020; 267: 1035–1042.
Google Scholar | Crossref | Medline50. Ontaneda, D, Tallantyre, EC, Raza, PC, et al. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: the DELIVER-MS study protocol. Contemp Clin Trials 2020; 95: 106009.
Google Scholar | Crossref | Medline51. Ontaneda, D, Tallantyre, E, Kalincik, T, et al. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol 2019; 18: 973–980.
Google Scholar | Crossref | Medline52. Ziemssen, T, Bass, AD, Berkovich, R, et al. Efficacy and safety of Alemtuzumab through 9 years of follow-up in patients with highly active disease: post hoc analysis of CARE-MS I and II patients in the TOPAZ extension study. CNS Drugs 2020; 34: 973–988.
Google Scholar | Crossref | Medline53. Brownlee, WJ, Altmann, DR, Prados, F, et al. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain 2019; 142: 2276–2287.
Google Scholar |